Stallergenes Greer decides to discontinue Palforzia
[(defatted powder of Arachis hypogaea L, semen (peanuts)]
Stallergenes Greer have decided to discontinue the marketing of Palforzia [(defatted powder of Arachis hypogaea L, semen (peanuts)] oral powder in capsules for opening (0.5 mg, 1 mg, 10 mg, 20 mg, 100 mg) and oral powder in sachet (300 mg) worldwide. Palforzia is indicated as a desensitization treatment for children with peanut allergy.
The decision is not related to the quality, safety or efficacy of the medicine, but is based on strategic and operational considerations at Stallergenes.
Stallergenes Greer said they are committed to allergy care, and take continued responsibility to Palforzia prescribers and patients very seriously. To ensure patients’ needs are prioritized and to allow sufficient time for clinical review and planning, a gradual discontinuation in the UK will be implemented as follows:
- 31st March 2026: Discontinuation of Palforzia initial dose escalation pack only.
- 31st March 2027: Discontinuation of Palforzia up-dosing packs (Levels 1-11)
Discontinuation of Palforzia maintenance pack
Until these dates, Palforzia will remain available, subject to existing supply conditions. Stallergenes Greer have said they encourage prescribers to take this discontinuation timeline into account when initiating new patients on treatment and to plan ongoing care for patients currently receiving Palforzia.
Healthcare professionals are reminded to continue reporting any suspected adverse reactions via the Yellow Card Scheme. Reporting forms and further information can be found here: https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to Stallergenes on 0800 0487 217 or [email protected].